PEN2: Metformin’s new partner at lysosome

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

PEN2 : Metformin’s new partner at lysosome. / Sakamoto, Kei; Jessen, Niels.

In: Cell Research, Vol. 32, 2022, p. 507-508.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Sakamoto, K & Jessen, N 2022, 'PEN2: Metformin’s new partner at lysosome', Cell Research, vol. 32, pp. 507-508. https://doi.org/10.1038/s41422-022-00661-7

APA

Sakamoto, K., & Jessen, N. (2022). PEN2: Metformin’s new partner at lysosome. Cell Research, 32, 507-508. https://doi.org/10.1038/s41422-022-00661-7

Vancouver

Sakamoto K, Jessen N. PEN2: Metformin’s new partner at lysosome. Cell Research. 2022;32:507-508. https://doi.org/10.1038/s41422-022-00661-7

Author

Sakamoto, Kei ; Jessen, Niels. / PEN2 : Metformin’s new partner at lysosome. In: Cell Research. 2022 ; Vol. 32. pp. 507-508.

Bibtex

@article{1df9e75236ec4fd68d2ab330c68235eb,
title = "PEN2: Metformin{\textquoteright}s new partner at lysosome",
abstract = "Metformin is the first-line therapy for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Ma and colleagues now identify a membrane protein PEN2 as a novel target of metformin at low concentrations which specifically activates lysosomal AMP-activated protein kinase (AMPK) via AMP-independent mechanism, leading to therapeutic benefits.",
author = "Kei Sakamoto and Niels Jessen",
year = "2022",
doi = "10.1038/s41422-022-00661-7",
language = "English",
volume = "32",
pages = "507--508",
journal = "Cell Research",
issn = "1001-0602",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - PEN2

T2 - Metformin’s new partner at lysosome

AU - Sakamoto, Kei

AU - Jessen, Niels

PY - 2022

Y1 - 2022

N2 - Metformin is the first-line therapy for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Ma and colleagues now identify a membrane protein PEN2 as a novel target of metformin at low concentrations which specifically activates lysosomal AMP-activated protein kinase (AMPK) via AMP-independent mechanism, leading to therapeutic benefits.

AB - Metformin is the first-line therapy for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Ma and colleagues now identify a membrane protein PEN2 as a novel target of metformin at low concentrations which specifically activates lysosomal AMP-activated protein kinase (AMPK) via AMP-independent mechanism, leading to therapeutic benefits.

U2 - 10.1038/s41422-022-00661-7

DO - 10.1038/s41422-022-00661-7

M3 - Journal article

C2 - 35418220

AN - SCOPUS:85129339624

VL - 32

SP - 507

EP - 508

JO - Cell Research

JF - Cell Research

SN - 1001-0602

ER -

ID: 307097381